Description

Overview
Survodutide (BI 456906) is a synthetic, long-acting dual receptor agonist peptide developed by Boehringer Ingelheim in collaboration with Zymeworks, simultaneously targeting both the Glucagon-like Peptide-1 (GLP-1) receptor and the Glucagon (GCGR) receptor. As a structurally distinct member of the GLP-1/glucagon dual agonist class alongside Mazdutide, Survodutide represents one of the most clinically advanced and scientifically compelling GLP-1/GCGR dual agonist compounds currently under active investigation, with a particularly strong and rapidly expanding research focus on non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and metabolic-associated steatotic liver disease (MASLD). Survodutide’s dual receptor pharmacology — combining GLP-1 receptor-mediated appetite suppression and insulinotropic effects with glucagon receptor-mediated enhancement of hepatic fat oxidation, energy expenditure, and thermogenesis — positions it as a uniquely differentiated research tool for studying the synergistic metabolic and hepatic consequences of simultaneous GLP-1 and glucagon receptor engagement. Apex Sequence Labs offers Survodutide at the highest purity standards, rigorously tested and manufactured under strict quality control protocols to ensure consistency and reliability for cutting-edge scientific research.

Molecular Profile

Full Name: Survodutide (BI 456906)
Type: Dual GLP-1/Glucagon Receptor Agonist
Developer: Boehringer Ingelheim / Zymeworks
Molecular Formula: C???H???N??O??S?
Molecular Weight: ~3298.7 g/mol
CAS Number: 2413928-16-0
Purity: 99% (HPLC verified)
Form: Lyophilized powder
Half-Life: Approximately 7 days (designed for once-weekly dosing in research models)

Research Areas of Interest
Survodutide has rapidly distinguished itself within the GLP-1/glucagon dual agonist research class through its particularly strong hepatic research profile, with a body of scientific investigation that spans metabolic science, hepatology, cardiovascular research, and obesity biology:

NASH, NAFLD & MASLD Research – The most scientifically prominent area of Survodutide investigation, and the research application that most distinguishes it within the broader GLP-1/glucagon dual agonist class. Research has documented Survodutide’s significant effects on hepatic steatosis, hepatic inflammation, hepatocyte ballooning, and fibrosis markers in preclinical and clinical research models. The dual mechanism of GLP-1 receptor-mediated reduction in hepatic lipid delivery through appetite suppression and weight loss, combined with glucagon receptor-mediated direct stimulation of hepatic fatty acid oxidation and reduction of de novo lipogenesis, positions Survodutide as one of the most mechanistically compelling compounds for NASH and MASLD research. Early clinical data has generated substantial scientific interest in Survodutide as a potential tool for studying the resolution of NASH histology and fibrosis regression in metabolic liver disease research models.
Hepatic Metabolism & Liver Biology Research – Beyond NASH and NAFLD, research has investigated Survodutide’s broader effects on hepatic metabolism, including its influence on hepatic glucose production, de novo lipogenesis, fatty acid oxidation pathways, ketone body production, bile acid metabolism, and overall hepatic energy substrate handling. The glucagon receptor component of Survodutide’s dual agonism is of particular scientific interest in hepatic research contexts, as hepatic glucagon receptor signalling is known to play a central role in regulating liver metabolism through multiple mechanisms including glycogenolysis, gluconeogenesis, fatty acid oxidation, and mitochondrial biogenesis in hepatocytes.
Metabolic Research & Energy Homeostasis – Investigated for its dual receptor-mediated effects on total energy expenditure, basal metabolic rate, and overall metabolic flexibility, with research exploring how the complementary mechanisms of GLP-1 receptor-mediated appetite suppression and glucagon receptor-mediated enhancement of energy expenditure interact to produce the observed metabolic phenotype. Studies have explored Survodutide’s effects on substrate utilisation, respiratory exchange ratio, and the partitioning of energy expenditure between different metabolic compartments in preclinical and clinical research models.
Body Composition & Obesity Research – Studied for its significant effects on body weight reduction and body composition remodelling, with research exploring the differential contributions of GLP-1 and glucagon receptor activation to fat mass reduction, lean mass preservation, and the overall composition of weight loss. Studies have investigated Survodutide’s effects on visceral versus subcutaneous adipose tissue, intrahepatic lipid content, and ectopic fat deposition in metabolic disease research models, with particular interest in whether glucagon receptor co-activation confers advantages over GLP-1 single agonism for visceral and hepatic fat reduction specifically.
Cardiovascular Research – Investigated for its potential cardioprotective and cardiometabolic effects in metabolic disease models, including improvements in lipid profiles, reductions in triglycerides, modulation of inflammatory cardiovascular risk markers, and effects on blood pressure and cardiac function. Research has explored the cardiovascular implications of glucagon receptor co-activation in the context of the established cardioprotective evidence base for GLP-1 receptor agonists, with studies examining whether the glucagon receptor component modifies, enhances, or attenuates the cardiovascular benefits associated with GLP-1 receptor agonism.
Glucose Metabolism & Glycaemic Research – Studied for its effects on insulin secretion, glucose-dependent insulinotropic activity, and glycaemic control through GLP-1 receptor activation, with research exploring how glucagon receptor co-activation influences hepatic glucose output and whether the net glycaemic effect of dual GLP-1/glucagon receptor engagement favours improved glucose homeostasis in metabolic disease research models. Studies have explored the fed versus fasted state dynamics of dual receptor engagement on postprandial and fasting glucose profiles in preclinical and clinical research settings.
Thermogenesis & Brown Adipose Tissue Research – Investigated for its glucagon receptor-mediated effects on brown adipose tissue (BAT) activation, uncoupling protein 1 (UCP1) expression, and non-shivering thermogenesis, with research exploring how Survodutide-stimulated glucagon receptor activation in BAT contributes to its overall energy expenditure profile and whether thermogenic enhancement represents a clinically meaningful component of its metabolic efficacy.
Fibrosis & Hepatic Stellate Cell Research – An important and distinctive area of Survodutide investigation within the NASH research context, studies have explored its effects on hepatic stellate cell activation, TGF-? signalling, collagen deposition, and fibrosis progression and regression markers in preclinical models of hepatic fibrosis. Research has examined whether the anti-fibrotic effects observed in Survodutide-treated research models are mediated through direct receptor-mediated mechanisms in hepatic stellate cells or are secondary to improvements in hepatic steatosis and inflammation.
Comparative Incretin Pharmacology Research – As the metabolic peptide research landscape has expanded to include GLP-1 single agonists, GIP/GLP-1 dual agonists (Tirzepatide), GLP-1/glucagon dual agonists (Survodutide, Mazdutide), and GIP/GLP-1/glucagon triple agonists (Retatrutide), Survodutide’s GLP-1/GCGR profile positions it as an essential comparator compound for researchers seeking to systematically map the individual and combined receptor contributions to metabolic, hepatic, and cardiovascular outcomes across the expanding incretin pharmacology research landscape.
Appetite & Satiety Neurobiology Research – Studied for its central and peripheral effects on appetite regulation through GLP-1 receptor activation, including modulation of hypothalamic hunger signalling pathways, gastric emptying dynamics, and satiety peptide release, with research exploring how glucagon receptor co-activation influences the overall appetite-suppressing phenotype and whether dual receptor engagement produces differentiated effects on food intake patterns compared to GLP-1 single agonism.

What Sets Survodutide Apart?
Survodutide’s scientific distinctiveness within the GLP-1/glucagon dual agonist class stems from several key features:

Hepatic Research Leadership – Among all GLP-1/glucagon dual agonist compounds, Survodutide has arguably the most advanced and compelling hepatic research profile, with clinical data from NASH and MASLD studies generating significant scientific interest in its potential to resolve NASH histology and reverse hepatic fibrosis — positioning it as the premier GLP-1/glucagon dual agonist research tool for liver disease research
Boehringer Ingelheim / Zymeworks Development Heritage – Developed through the collaboration of two scientifically rigorous pharmaceutical organisations with complementary expertise in metabolic and protein engineering research, Survodutide benefits from a sophisticated structural optimisation programme designed to maximise dual receptor potency, selectivity, and pharmacokinetic stability
MASLD Research Relevance – As scientific nomenclature has evolved from NAFLD/NASH to MASLD/MASH, Survodutide’s research profile positions it at the forefront of the most current and scientifically relevant liver disease research framework, making it a timely and forward-looking research tool for hepatic metabolic disease investigation
Mechanistically Complementary Hepatic Effects – The combination of GLP-1 receptor-mediated reduction in hepatic lipid influx and glucagon receptor-mediated direct stimulation of hepatic fat oxidation represents a mechanistically complementary dual approach to hepatic fat reduction that is unique to the GLP-1/glucagon dual agonist class and not accessible through GLP-1 or GIP receptor agonism alone
Critical Comparator in Incretin Pharmacology Research – Alongside Mazdutide, Survodutide provides researchers with a second, structurally distinct GLP-1/glucagon dual agonist, enabling comparative studies of GLP-1/GCGR dual agonist pharmacology across different structural scaffolds and enabling more robust conclusions about the class effects versus compound-specific effects of GLP-1/glucagon dual receptor engagement

Quality Assurance
All Apex Sequence Labs peptides are:

Synthesized using advanced solid-phase peptide synthesis (SPPS)
Third-party tested via HPLC and Mass Spectrometry
Produced in a controlled, sterile, ISO-compliant laboratory environment
Supplied with a Certificate of Analysis (CoA) available upon request

Packaging & Storage

Available in: 2mg | 5mg | 10mg vials
Storage: Store lyophilized peptide at 20°C away from light and moisture
Once reconstituted: Store at 4°C and use within 28 days
Recommended diluent: Bacteriostatic water or sterile water for injection
Shelf life: 24 months when stored correctly in lyophilized form

Why Choose Apex Sequence Labs?

– 99% purity guaranteed
– Independent third-party testing on every batch
– Certificate of Analysis provided
– Produced in ISO-compliant cleanroom facilities
– Fast, discreet shipping
– Dedicated researcher support team

– Research Use Only Disclaimer
Survodutide supplied by Apex Sequence Labs is intended strictly for in vitro and in vivo laboratory research purposes only. This product is NOT intended for human or veterinary use, is NOT a drug or dietary supplement, and has NOT been evaluated or approved by the FDA or any other regulatory authority for therapeutic, diagnostic, or prophylactic use. Survodutide is an investigational compound currently undergoing clinical evaluation and is not approved for any clinical or consumer application. By purchasing this product, the buyer confirms they are a qualified researcher and accepts full responsibility for its lawful and ethical use in accordance with all applicable local, state, and federal regulations.